Page 50 - Read Online

marker of response. However, the persistence of high Ethics approval
levels of Ga-DOTATATE uptake during treatment with This article does not contain any studies with human
68
SSAs can suggest the continuation of cold SSAs treatment participants or animals.
in patients with stable disease and/or to switch to PRRT in
patients with signs of clinical/radiological worsening. [52] REFERENCES

18 F-FDG PET/CT may be useful, instead, in the evaluation 1. Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring
of patients with dedifferentiated tumor recurrences and the rising incidence of neuroendocrine tumors: a population-based
[69]
of patients who had F-FDG-avid lesions at diagnosis analysis of epidemiology, metastatic presentation, and outcomes:
18
neuroendocrine tumor epidemiology. Cancer 2015;121:589-97.
in whom changes in F-FDG SUV between pre-therapy 2. Garin E, Jeune FL, Devillers A, Cuggia M, de Lajarte-Thirouard AS,
18
baseline and intratherapy follow-up scans may be an Bouriel C, Boucher E, Raoul JL. Predictive value of 18F-FDG PET
indicator of response to treatment. In this context it may and Somatostatin receptor scintigraphy in patients with metastatic
be useful to refer to a standardized set of rules which endocrine tumors. J Nucl Med 2009;50:858-64.
can be employed to objectively assess tumor response 3. Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE,
to treatment such as PERCIST criteria which were Imperiale A. Nuclear medicine imaging of gastro-entero-pancreatic
neuroendocrine tumors. The key role of cellular differentiation
developed for quantitative PET evaluation of changes and tumor grade: from theory to clinical practice. Cancer Imaging
in tumor metabolic activity induced by anticancer 2012;12:173-84.
treatments. For instance, the use of these criteria has 4. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch
[70]
shown to be clinically useful in the evaluation of patients A, Kuehl H, Li J, Broelsch CE. The impact of 68Ga-DOTATOC
with SCLC. [71] positron emission tomography/computed tomography on the
multimodal management of patients with neuroendocrine tumors.
CONCLUSION 5. Ann Surg 2010;252:850-6.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715
carcinoid tumors. Cancer 2003;97:934-59.
Double-tracer PET/CT is a useful tool in the management 6. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW,
of NENs. Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP,
Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin
Parameters that may influence the decision of the clinician A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol
to request a double-tracer PET/CT study are include 7. 2008;9:61-72.
Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK,
tumor grading, primary tumor site and clinical setting (i.e. Winchester DP, Ko CY, Bentrem DJ. Prognostic score predicting
resectable vs. advanced disease, etc.). survival after resection of pancreatic neuroendocrine tumors:
analysis of 3851 patients. Ann Surg 2008;247:490-500.
68 Ga-DOTA-peptide PET/CT is routinely employed in the 8. Rufini V, Baum RP, Castaldi P, Treglia G, Gaetano AMD, Carreras
setting of low- and intermediate-grade NENs; F-FDG C, Kaemmerer D, Hommann M, Hörsch D, Bonomo L, Giordano A.
18
PET/CT has a more debated role in the management of Role of PET/CT in the functional imaging of endocrine pancreatic
tumors. Abdom Imaging 2012;37:1004-20.
NENs. Besides its established role in the management of 9. Reubi JC. Peptide receptors as molecular targets for cancer
highly proliferating neoplasms, it can be a useful tool even diagnosis and therapy. Endocr Rev 2003;24:389-427.
in more indolent tumors. 10. Ezziddin S, Logvinski T, Yong-Hing C, Ahmadzadehfar H, Fischer
HP, Palmedo H, Bucerius J, Reinhardt MJ, Biersack HJ. Factors
Double-tracer PET/CT may have not only diagnostic, but predicting tracer uptake in somatostatin receptor and MIBG
also predictive and prognostic applications. Double-tracer scintigraphy of metastatic gastroenteropancreatic neuroendocrine
tumors. J Nucl Med 2006;47:223-33.
staging shows a higher overall accuracy than conventional 11. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH,
imaging and can provide prognostic information. A Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron
possible predictive role of nuclear medical imaging has emission tomography for the imaging of neuroendocrine tumours.
been suggested, but has not yet been fully validated. Eur J Nucl Med 1998;25:79-83.
Although Ga-DOTA-peptide PET/CT has been found 12. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti
68
in several studies to be a strong predictor of response to F, Ferlin G, Pedrazzoli S. Neuroendocrine tumor imaging: can
PRRT, the role of 18F-FDG PET/CT as a predictive factor 18F-fluorodeoxyglucose positron emission tomography detect
tumors with poor prognosis and aggressive behavior? World J Surg
is still under investigation. 1998;22:588-92.
13. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P,
Financial support and sponsorship Hustinx R. Fluorodeoxyglucose positron emission tomography
Nil. and somatostatin receptor scintigraphy for diagnosing and staging
carcinoid tumours: correlations with the pathological indexes p53
Conflicts of interest and Ki-67. Nucl Med Commun 2002;23:727-34.
There are no conflicts of interest. 14. Adams S, Baum RP, Hertel A, Schumm-Dräger PM, Usadel KH,
Hör G. Metabolic (PET) and receptor (SPET) imaging of well- and
less well-differentiated tumours: comparison with the expression of
Patient consent the Ki-67 antigen. Nucl Med Commun 1998;19:641-7.
No patient involved. 15. Schiepers C, Allen-Auerbach M. Eds, Diagnostic nuclear medicine:
326
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦